DZ2539A1 - Compositions pharmaceutiques pour le traitement dela résistance à l'insuline. - Google Patents
Compositions pharmaceutiques pour le traitement dela résistance à l'insuline.Info
- Publication number
- DZ2539A1 DZ2539A1 DZ980149A DZ980149A DZ2539A1 DZ 2539 A1 DZ2539 A1 DZ 2539A1 DZ 980149 A DZ980149 A DZ 980149A DZ 980149 A DZ980149 A DZ 980149A DZ 2539 A1 DZ2539 A1 DZ 2539A1
- Authority
- DZ
- Algeria
- Prior art keywords
- treatment
- pharmaceutical compositions
- insulin resistance
- insulin
- resistance
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5079097P | 1997-06-25 | 1997-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
DZ2539A1 true DZ2539A1 (fr) | 2003-02-08 |
Family
ID=21967444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DZ980149A DZ2539A1 (fr) | 1997-06-25 | 1998-06-24 | Compositions pharmaceutiques pour le traitement dela résistance à l'insuline. |
Country Status (41)
Country | Link |
---|---|
US (3) | US6448263B1 (uk) |
EP (1) | EP1000085B1 (uk) |
JP (2) | JP2000514099A (uk) |
KR (1) | KR20010014224A (uk) |
CN (2) | CN1152049C (uk) |
AP (1) | AP1145A (uk) |
AR (1) | AR012256A1 (uk) |
AT (1) | ATE305477T1 (uk) |
AU (1) | AU747510B2 (uk) |
BG (1) | BG104008A (uk) |
BR (1) | BR9810477A (uk) |
CA (1) | CA2294464A1 (uk) |
CO (1) | CO4950621A1 (uk) |
DE (1) | DE69831745T2 (uk) |
DZ (1) | DZ2539A1 (uk) |
EA (1) | EA002089B1 (uk) |
EG (1) | EG21712A (uk) |
ES (1) | ES2248899T3 (uk) |
HK (1) | HK1028051A1 (uk) |
HN (1) | HN1998000088A (uk) |
HR (1) | HRP980361A2 (uk) |
HU (1) | HUP0001922A3 (uk) |
ID (1) | ID24345A (uk) |
IL (7) | IL154116A0 (uk) |
IN (1) | IN189724B (uk) |
IS (1) | IS5275A (uk) |
MA (1) | MA24581A1 (uk) |
NO (1) | NO996205L (uk) |
NZ (1) | NZ500655A (uk) |
OA (1) | OA11242A (uk) |
PA (1) | PA8452601A1 (uk) |
PE (1) | PE105399A1 (uk) |
PL (1) | PL337659A1 (uk) |
SK (1) | SK175699A3 (uk) |
TN (1) | TNSN98113A1 (uk) |
TR (1) | TR199903257T2 (uk) |
TW (1) | TW553943B (uk) |
UA (1) | UA64751C2 (uk) |
WO (1) | WO1998058949A1 (uk) |
YU (1) | YU70199A (uk) |
ZA (1) | ZA985546B (uk) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
US6541634B2 (en) | 1999-02-26 | 2003-04-01 | Pfizer Inc. | Process for preparing growth hormone secretagogues |
US7721948B1 (en) * | 1999-05-25 | 2010-05-25 | Silverbrook Research Pty Ltd | Method and system for online payments |
EP1132388A3 (en) * | 2000-03-09 | 2004-03-03 | Pfizer Products Inc. | Hexahydropyrazolo[4,3-c]pyridine metabolites |
EP1159964B1 (en) | 2000-05-31 | 2009-10-28 | Pfizer Products Inc. | Use of growth hormone secretagogues for stimulating gastrointestinal motility |
IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
CA2496687A1 (en) * | 2002-09-18 | 2004-04-01 | Centre Hospitalier De L'universite De Montreal (Chum) | Ghrh analogues |
US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
US7828934B2 (en) * | 2004-12-21 | 2010-11-09 | Hercules Incorporated | Reactive cationic resins for use as dry and wet strength agents in sulfite ion-containing papermaking systems |
US20070024388A1 (en) * | 2005-07-27 | 2007-02-01 | Hassan Tanbakuchi | Slabline structure with rotationally offset ground |
CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
BRPI0807046A2 (pt) | 2007-02-09 | 2015-05-26 | Tranzyme Pharma Inc | Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit. |
US7862825B2 (en) * | 2007-02-21 | 2011-01-04 | Mladen Vranic | Method of controlling tight blood glucose by somatostatin receptor antagonists |
AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
AU2013255458A1 (en) | 2012-05-03 | 2014-10-09 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
CN105164129B (zh) | 2013-05-28 | 2018-01-19 | 拉夸里亚创药株式会社 | 多晶型物形式 |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
JP6051392B1 (ja) * | 2014-08-05 | 2016-12-27 | ラクオリア創薬株式会社 | グレリン受容体アゴニストとしてのセリン誘導体 |
EP3212648A1 (en) * | 2014-10-31 | 2017-09-06 | RaQualia Pharma Inc. | Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists |
US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3235550A (en) | 1966-02-15 | Anal g gesiaxoat t tail intravenous injection | ||
US3190802A (en) | 1961-10-09 | 1965-06-22 | Boehringer Sohn Ingelheim | Shaving composition and method of using same |
US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
GB2101114B (en) | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
US5242783A (en) | 1991-07-31 | 1993-09-07 | Eastman Kodak Company | Photographic material and process |
CA2147503A1 (en) | 1992-11-06 | 1994-05-26 | Judith M. Pisano | Substituted dipeptide analogs promote release of growth hormone |
RU2168512C2 (ru) | 1992-12-11 | 2001-06-10 | Мерк Энд Ко., Инк. | Спиропиперидины, способы их получения (варианты) |
EP0739204A4 (en) | 1993-11-09 | 2000-03-15 | Merck & Co Inc | PIPERIDINE, PYRROLIDINE AND HEXAHYDRO-1H-AZEPINE SUPPORT THE RELEASE OF THE GROWTH HORMONE |
US5492916A (en) * | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
BR9610277A (pt) | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
EP0766966A3 (en) | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
PL327227A1 (en) | 1995-12-22 | 1998-12-07 | Novo Nordisk As | Compounds exhibiting growth hormone liberating properties |
TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
AU7445498A (en) * | 1997-06-25 | 1999-01-04 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
-
1998
- 1998-05-06 UA UA99127068A patent/UA64751C2/uk unknown
- 1998-06-04 HN HN1998000088A patent/HN1998000088A/es unknown
- 1998-06-05 IL IL15411698A patent/IL154116A0/xx unknown
- 1998-06-05 CN CNB988059231A patent/CN1152049C/zh not_active Expired - Fee Related
- 1998-06-05 IL IL13362698A patent/IL133626A0/xx unknown
- 1998-06-05 CA CA002294464A patent/CA2294464A1/en not_active Abandoned
- 1998-06-05 WO PCT/IB1998/000876 patent/WO1998058949A1/en not_active Application Discontinuation
- 1998-06-05 YU YU70199A patent/YU70199A/sh unknown
- 1998-06-05 ES ES98921683T patent/ES2248899T3/es not_active Expired - Lifetime
- 1998-06-05 IL IL15646598A patent/IL156465A/en not_active IP Right Cessation
- 1998-06-05 DE DE69831745T patent/DE69831745T2/de not_active Expired - Fee Related
- 1998-06-05 ID IDW991668A patent/ID24345A/id unknown
- 1998-06-05 IL IL15411198A patent/IL154111A0/xx unknown
- 1998-06-05 SK SK1756-99A patent/SK175699A3/sk unknown
- 1998-06-05 AT AT98921683T patent/ATE305477T1/de not_active IP Right Cessation
- 1998-06-05 TR TR1999/03257T patent/TR199903257T2/xx unknown
- 1998-06-05 PA PA19988452601A patent/PA8452601A1/es unknown
- 1998-06-05 JP JP11504029A patent/JP2000514099A/ja not_active Withdrawn
- 1998-06-05 EA EA199901075A patent/EA002089B1/ru not_active IP Right Cessation
- 1998-06-05 NZ NZ500655A patent/NZ500655A/en unknown
- 1998-06-05 AU AU74456/98A patent/AU747510B2/en not_active Ceased
- 1998-06-05 CN CNA2004100334189A patent/CN1530107A/zh active Pending
- 1998-06-05 IL IL15411598A patent/IL154115A0/xx unknown
- 1998-06-05 US US09/380,186 patent/US6448263B1/en not_active Expired - Fee Related
- 1998-06-05 PL PL98337659A patent/PL337659A1/xx unknown
- 1998-06-05 HU HU0001922A patent/HUP0001922A3/hu unknown
- 1998-06-05 EP EP98921683A patent/EP1000085B1/en not_active Expired - Lifetime
- 1998-06-05 IL IL15411498A patent/IL154114A0/xx unknown
- 1998-06-05 IL IL15411298A patent/IL154112A0/xx unknown
- 1998-06-05 BR BRPI9810477-2A patent/BR9810477A/pt not_active Application Discontinuation
- 1998-06-05 KR KR1019997012312A patent/KR20010014224A/ko active Search and Examination
- 1998-06-18 AP APAP/P/1998/001267A patent/AP1145A/en active
- 1998-06-22 TW TW087110014A patent/TW553943B/zh not_active IP Right Cessation
- 1998-06-22 PE PE1998000546A patent/PE105399A1/es not_active Application Discontinuation
- 1998-06-23 EG EG73598A patent/EG21712A/xx active
- 1998-06-23 AR ARP980103023A patent/AR012256A1/es not_active Application Discontinuation
- 1998-06-24 MA MA25139A patent/MA24581A1/fr unknown
- 1998-06-24 TN TNTNSN98113A patent/TNSN98113A1/fr unknown
- 1998-06-24 IN IN1755DE1998 patent/IN189724B/en unknown
- 1998-06-24 DZ DZ980149A patent/DZ2539A1/xx active
- 1998-06-25 ZA ZA9805546A patent/ZA985546B/xx unknown
- 1998-06-25 CO CO98036379A patent/CO4950621A1/es unknown
- 1998-06-25 HR HR60/050,790A patent/HRP980361A2/hr not_active Application Discontinuation
-
1999
- 1999-11-26 IS IS5275A patent/IS5275A/is unknown
- 1999-12-14 BG BG104008A patent/BG104008A/xx unknown
- 1999-12-15 NO NO996205A patent/NO996205L/no not_active Application Discontinuation
- 1999-12-21 OA OA9900300A patent/OA11242A/en unknown
-
2000
- 2000-11-23 HK HK00107485A patent/HK1028051A1/xx not_active IP Right Cessation
-
2002
- 2002-05-29 US US10/158,649 patent/US6630487B2/en not_active Expired - Fee Related
-
2003
- 2003-07-22 US US10/626,198 patent/US6867202B1/en not_active Expired - Fee Related
-
2004
- 2004-08-04 JP JP2004228301A patent/JP3742643B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DZ2539A1 (fr) | Compositions pharmaceutiques pour le traitement dela résistance à l'insuline. | |
DZ2494A1 (fr) | Composition pharmaceutique d'oméprazole. | |
ITRM910696A1 (it) | Composizioni farmaceutiche per l'applicazione per via nasale. | |
FR2705566B1 (fr) | Nouvelles compositions pharmaceutiques. | |
DZ2752A1 (fr) | Composés et compositions pharmaceutiques pour le traitement du paludisme. | |
NO20006630D0 (no) | Farmasöytisk sammensetning for behandlingen av diabetes | |
FI973828A (fi) | Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi | |
DZ3191A1 (fr) | Composés d'indazole et compositions pharmaceutiques inhibant les protéines kinases, et procédés d'utilisation de ceux-ci. | |
MA26790A1 (fr) | Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie | |
MA26553A1 (fr) | Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la | |
FR2687573B1 (fr) | Composition pour application nasale. | |
FI953915A0 (fi) | Dupuytrenin taudin lievittämiseen | |
DZ3014A1 (fr) | Médicaments pour le traitement de l'hypertension. | |
IT1295645B1 (it) | Apparecchio per l'elettroemanazione di principi attivi. | |
DZ1559A1 (fr) | Compositions pharmaceutiques. | |
FR2753376B1 (fr) | Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques | |
NO950134D0 (no) | Formuleringer for oralt administrerte farmasöytiske midler | |
FR2712495B1 (fr) | Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant. | |
BR9507768A (pt) | Composição farmacêutica | |
DZ1926A1 (fr) | Formulations pharmaceutiques. | |
FR2758465B1 (fr) | Composition pour le traitement de l'amiante | |
BR9806083A (pt) | Composi-Æo farmac-utica para o tratamento da hapattite c | |
DZ2564A1 (fr) | Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés. | |
ZA989238B (en) | Benzimidazole compounds pharmaceutical compositions containing the compounds and their use | |
FR2695297B1 (fr) | Composition d'agent désinfectant. |